Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
US11421034B2 · kind B2 · utility
0Cited by
16References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 12, 2018 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Sep 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.